This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).
Over the recent decades, cancer immunotherapy research has made significant advances. In our continued quest to cure cancer, a commercial incentive is necessary to counterbalance the costs and risks associated with the research and development of cancer immunotherapies and to encourage new inventions.
Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.
Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]
– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]
The George Washington University (GW) Technology Commercialization Office is pleased to host the inaugural DC Startup Showcase.DC Startup Showcase will present companies developing disruptive healthcare innovations. Log on to our [….]
Nick Fullenkamp Appointed Chief Business Officer at Avidea Technologies, Inc. Nick Fullenkamp, M.B.A. has joined Avidea Technologies as Chief Business Officer and will be leading Business Development, financing strategy and [….]
Breakthrough in Vaccine 2020 Conference Event Name: 3rd International Conference Vaccines & Vaccination (Vaccine 2020)| May 20-21, 2020 Theme: Advances in Immunology & Vaccine Technology and Their Impact Aim and [….]
Weekly Roundup of COVID-19 Progress From T-Cell to Microbiome Therapies and FDA Emergency Use Applications April 21, 2020 Organizations from across the BioHealth Capital Region (BCHR) continue to pivot research, [….]
